Renal toxicity of targeted therapies
| Autor: | Olivier Rixe, Ronan J. Kelly, B. Billemont |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Niacinamide
Vascular Endothelial Growth Factor A Cancer Research Indoles Pyridines medicine.medical_treatment Drug Evaluation Preclinical Antibodies Monoclonal Humanized Kidney Bioinformatics Nephropathy Targeted therapy Nephrotoxicity Neoplasms Sunitinib medicine Humans Pyrroles Pharmacology (medical) Protein Kinase Inhibitors Clinical Trials as Topic Neovascularization Pathologic business.industry Phenylurea Compounds Benzenesulfonates Antibodies Monoclonal Cancer Sorafenib medicine.disease Review article Bevacizumab Proteinuria medicine.anatomical_structure Oncology Hypertension Immunology business Kidney disease medicine.drug |
| Zdroj: | Targeted Oncology. 4:121-133 |
| ISSN: | 1776-260X 1776-2596 |
| DOI: | 10.1007/s11523-009-0109-x |
| Popis: | The use of molecular targeted therapies for the treatment of cancer has increased over the last decade. The benefits of these compounds in terms of efficacy are often relatively modest and counter balanced by the occurrence of significant toxicities. Many of these newer agents used in clinical practice lack specificity and selectivity and have a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity are poorly defined and numerous class-specific toxicities have been described. The kidney is an organ where most of these targeted pathways are expressed. Preclinical data and human renal biopsies have generated an understanding of the mechanisms involved in how targeted agents can cause renal toxicity. This review article discusses the observed nephrotoxicity with this burgeoning class of therapeutics and reviews both the biological reasons for its occurrence and possible ways to prevent significant renal damage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink